Journal
GUT
Volume 60, Issue 1, Pages 116-129Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/gut.2009.206250
Keywords
-
Categories
Funding
- Burroughs Welcome Fund Clinical Scientist in Translational Research Award [NCI RO1CA115513, P30 CA015704]
- NATIONAL CANCER INSTITUTE [P30CA015704, R01CA115513, P01CA077852] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The promise of personalised medicine is now a clinical reality, with colorectal cancer genetics at the forefront of this next major advance in clinical medicine. This is no more evident than in the recent advances in testing of colorectal cancers for specific molecular alterations in order to guide treatment with the monoclonal antibody therapies cetuximab and panitumumab, which target the epidermal growth factor receptor. In this review, genetic mechanisms of colorectal cancer and how these alterations relate to emerging biomarkers for early detection and risk stratification (diagnostic markers), prognosis (prognostic markers) and the prediction of treatment responses (predictive markers) are examined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available